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A B S T R A C T
This is a protocol for a Cochrane Review (Methodology). The objectives are as follows:
To assess the effects of ’Summary of findings’ tables on communicating key findings of systematic reviews of the effects of healthcare
interventions.
This will be achieved by:
• assessing the effects of ’Summary of findings’ tables versus full versions of systematic reviews on communicating key findings of
systematic reviews of the effects of healthcare interventions;
• assessing the effects of ’Summary of findings’ tables plus full review versus full review (no ’Summary of findings’ tables);
• assessing the effects of ’Summary of findings’ tables versus other summaries of systematic reviews on communicating key
findings of systematic reviews of the effects of healthcare interventions;
• assessing the effects of interactive ’Summary of findings’ tables versus static ’Summary of findings’ tables on communicating key
findings of systematic reviews of the effects of healthcare interventions;
• assessing the effects of ’Summary of findings’ tables versus other formats of ’Summary of findings’ tables on communicating key
findings of systematic reviews of the effects of healthcare interventions;
• assessing how particular participant groups e.g. patients, healthcare providers, policy makers, understand and apply the
information from the ’Summary of findings’ tables.
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B A C K G R O U N D
Description of the problem or issue
Systematic reviews of randomised trials of the effects of healthcare
interventions are important sources of evidence to inform health-
care decisions (Manheimer 2012). Grimshaw 2012 suggests that
systematic reviews and other research syntheses should be the basic
unit of knowledge translation. Elsewhere, they have beendescribed
as one of the most important tools for getting evidence into prac-
tice (Carrasco-Labra 2015). Well-conducted systematic reviews
contain the depth of information and optimal methodology to
best inform users for the decision-making process (Ganann 2010).
The number of available systematic reviews is growing rapidly
(Bastian 2010). By October 2016, there were 7066 full Cochrane
reviews published in the Cochrane Database of Systematic Reviews
(Cochrane 2016). Moher 2007 found superior reporting stan-
dards in Cochrane reviews compared with non-Cochrane reviews
and Lundh 2009 found that Cochrane reviews were of a higher
methodological quality than non-Cochrane reviews. However, de-
spite the quality of evidence offered by systematic reviews, uptake
of the main findings can be slow or may not happen (Murthy
2012). Waddell 2001 explored dissemination and uptake prob-
lems associated with research evidence, one of which was the in-
creasing volume of available evidence. The overload of informa-
tion available in print and electronic formats can make it difficult
to find answers to healthcare questions about the effectiveness of
healthcare interventions. Bastian 2010 counted the publication of
75 trials and 11 systematic reviews of trials daily and highlighted
that this number is growing. In amore recent cross-sectional study,
Page 2016 counted 682 systematic reviews indexed inMEDLINE
in February 2014. This is equivalent to more than 8000 each year,
or 22 per day. The authors calculated that this represents a three-
fold increase on 2004 figures.
In a systematic review, Wallace 2012 explored barriers to the use
of systematic reviews including; time required to read, the com-
plex nature of their methods and statistics, and lack of user access,
perceived usefulness, awareness and training. They identified 28
barriers to the use of research evidence from systematic reviews
by decision makers. They divided these barriers into three broad
categories: knowledge, attitudinal and behavioural. These factors
can have a negative impact on the ability and willingness of po-
tential review users to engage with full versions of systematic re-
views. Previous studies exploring information seeking behaviour
of physicians revealed the lack of use of current evidence from
electronic sources (Dawes 2003; Coumou 2006; Hider 2009). In
the systematic review by Dawes 2003, of the 19 included studies,
the primary information source for physicians was text sources
(textbooks, papers or desk reference) in 13 studies, consultations
with colleagues in four studies and electronic sources in one study.
It has been recommended that three interventions will improve
uptake of systematic reviews: targeted messaging, educational vis-
its and systematic review summaries.
In this review, we will focus on systematic review summaries
(Wallace 2014). There are several types of summaries of systematic
reviews including plain language summaries (clear, concise and jar-
gon-free summaries of the key question and findings of a system-
atic review (Chandler 2013), GRADE evidence profiles (similar
to ’Summary of findings’ tables but also featuring a rationale for
the quality of evidence rating (Guyatt 2011)), and ’Summary of
findings’ tables (Guyatt 2008; Manheimer 2012; Carrasco-Labra
2015). ’Summary of findings’ tables are a widely-recognised sum-
marisationmethod. According to the updatedMethodological Ex-
pectations of Cochrane Intervention Reviews standards, they are
recommended as “highly desirable” for inclusion in newCochrane
reviews and in the protocol it is mandatory for authors to put a
plan in place for their inclusion (Higgins 2016). Chapter 11 of the
Cochrane Handbook for Systematic Reviews of Interventions details
how to produce and present ’Summary of findings’ tables. They
are also increasingly featured in non-Cochrane systematic reviews
(Langendam 2013). One mixed-methods study, incorporating a
randomised trial and follow-up participant interviews, compared
providing participants with systematic reviews with and without a
’Summary of findings’ table, and ’graded-entry’ formats (a ’front-
end’ summary and a contextually framed narrative report plus the
review). There were no differences between groups for the primary
outcome of correct responses to a test of key clinical questions on
specific topics (adjusted odds ratios (ORs): systematic review with
’Summary of findings’ table versus systematic review alone 0.59,
95% confidence interval (CI) 0.32 to 1.07; ‘graded-entry format
versus systematic review alone 0.66, 95% CI 0.36 to 1.21). How-
ever, graded-entry formats received a higher composite score than
systematic reviews alone for their clarity and ease of use (adjusted
mean difference (MD) 0.52, 95% CI 0.06 to 0.99). Findings were
conflicting with some users finding ’Summary of findings’ tables
useful for “rapid consultation”, while others reported that they
were difficult to understand without supplementary information
(Opiyo 2013).
Description of the methods being investigated
’Summary of findings’ tables are designed to present key findings
of systematic reviews in a clear and concise format. The main
elements of a ’Summary of findings’ table are:
• a description of patient/population/problem, intervention
and comparator(s) and all desirable and undesirable outcomes
(PICO);
• a description of the study setting;
• the number of participants;
• the number of studies addressing each outcome;
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• a measure of the assumed risk in the control group and the
corresponding risk in the intervention group;
• the relative effect (risk ratio) or other measures of effect;
• the mean difference or standardised mean difference and
confidence interval;
• the certainty of the evidence according to the GRADE
classification terms listed in the section ‘Summarising and
interpreting results’;
• a comments section.
In this Cochrane review, we will include studies assessing the ef-
fects of interactive or static ’Summary of findings’ tables as an in-
tervention to communicate key findings of systematic reviews of
the effects of healthcare interventions. The interactive format has
additional functionality compared to the traditional static version
by providing users with an option to view varying depths of in-
formation and complexity (DECIDE 2014). We will also include
narrative ’Summary of findings’ tables where results have not been
pooled in a meta-analysis or when units of analysis cannot be com-
pared. These are ’Summary of findings’ tables where authors enter
a narrative description of the effect of the outcome. The ’Sum-
mary of findings’ table is evolving in accordance with feedback
from users. The GRADEpro Guideline Development Tool (now
also called GRADEpro GDT app) is an online software which
enables authors of reviews and guideline developers to create their
own ’Summary of findings’ tables (Treweek 2013). ’Summary of
findings’ tables can also be created on the Epistemonikos website.
More recently, summary of qualitative findings tables have been
introduced to summarise the key findings from qualitative evi-
dence syntheses. These involve using the GRADE-CERQual ap-
proach to assess the confidence in the evidence for each finding
(Lewin 2015).
How these methods might work
The ’Summary of findings’ table may have an impact by com-
municating key findings of systematic reviews of healthcare in-
terventions to patients, healthcare staff, policy makers and other
stakeholders by providing a summary with clear information pre-
sented in a user-friendly format (Glenton 2006). A recent study
found that it is possible for users to understand key findings of
Cochrane systematic reviews using summary formats (Maguire
2014). Rosenbaum 2010 conducted a study to design a ’Sum-
mary of findings’ table for Cochrane reviews that would be useful
to stakeholders. They used an iterative process of brainstorming
workshops, advisory group feedback and user testing to develop a
’Summary of findings’ table. Participants included attendees of a
workshop for beginners to evidence-based practice inNorway and,
clinicians and research-related professionals from the UK. Most
of the changes to the table addressed the issues of usability and
usefulness. The aim is to resolve “the tension between achieving
table precision and table simplicity” (Rosenbaum 2010).
In anunpublished study reported byLangendam 2013, researchers
found that the layout of a ’Summary of findings’ table for a
Cochrane systematic review was clear, helpful for presenting re-
sults and increased accessibility of the systematic review. However,
these findings related to a very specific participant group made up
of members of Cochrane review groups and cannot be assumed to
be widely transferable.
Why it is important to do this review
’Summary of findings’ tables offer users a reduced volume of in-
formation when compared to full systematic reviews based on the
same high-quality methodology of the systematic review to sup-
port the content. Lavis 2009 highlighted the need for summaries of
systematic reviews featuring decision-relevant information. This
review will provide a single source of evidence for effectiveness of
’Summary of findings’ tables when compared to full versions or
summaries of systematic reviews.
The potential beneficiaries of this review are systematic review au-
thors because it may provide them with evidence to support the
inclusion or exclusion of ’Summary of findings’ tables in their re-
views. If ’Summary of findings’ tables support communication,
then this review will also benefit potential users of systematic re-
views such as clinicians, guideline developers, healthcare users,
policy makers and other stakeholders e.g. charitable organisations,
the patient population, the public and individuals or groups who
inform them, by providing evidence in a form which allows them
to quickly access and understand key findings of future reviews. It
may also support these users in making decisions about whether to
create ’Summary of findings’ tables to disseminate review findings
(and potentially other research findings) within their own organ-
isations.
The inclusionof ’Summary of findings’ tables in systematic reviews
is recommended in publications such as the Cochrane Handbook of
Systematic Reviews of Interventions (Higgins 2011) and the Grad-
ing of Recommendations Assessment, Development, and Evalua-
tion (GRADE) Working Group guidelines (Guyatt 2011; Guyatt
2013a; Guyatt 2013b). This review is timely and important be-
cause ’Summary of findings’ tables are commonly used to dissemi-
nate the key findings of Cochrane systematic reviews yet there is no
systematic review to synthesise the evidence of their effectiveness
at communicating review results. Although this systematic review
asks a focused question about the effectiveness of ’Summary of
findings’ tables, it relates to larger problems of healthcare informa-
tion overload, training requirements for stakeholders in (1) the in-
terpretation and use of statistics and (2) critical appraisal, and (3)
the lack of time healthcare professionals have to spend reviewing
evidence during decision-making and daily patient management.
O B J E C T I V E S
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To assess the effects of ’Summary of findings’ tables on communi-
cating key findings of systematic reviews of the effects of health-
care interventions.
This will be achieved by:
• assessing the effects of ’Summary of findings’ tables versus
full versions of systematic reviews on communicating key
findings of systematic reviews of the effects of healthcare
interventions;
• assessing the effects of ’Summary of findings’ tables plus full
review versus full review (no ’Summary of findings’ tables);
• assessing the effects of ’Summary of findings’ tables versus
other summaries of systematic reviews on communicating key
findings of systematic reviews of the effects of healthcare
interventions;
• assessing the effects of interactive ’Summary of findings’
tables versus static ’Summary of findings’ tables on
communicating key findings of systematic reviews of the effects
of healthcare interventions;
• assessing the effects of ’Summary of findings’ tables versus
other formats of ’Summary of findings’ tables on communicating
key findings of systematic reviews of the effects of healthcare
interventions;
• assessing how particular participant groups e.g. patients,
healthcare providers, policy makers, understand and apply the
information from the ’Summary of findings’ tables.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will consider three types of study design where effects of ex-
posure to ’Summary of findings’ tables of systematic reviews of
the effects of healthcare interventions on one or more outcome is
measured:
• randomised trials;
• non-randomised trials;
• cross-over trials.
We will follow the Cochrane Effective Practice and Organisation
of Care (EPOC) Group definitions of these experimental study
types (EPOC 2013a).We will include both published and unpub-
lished studies. We anticipate few randomised trials on this topic
because ’Summary of findings’ tables are a relatively new inter-
vention. Therefore, we have broadened our inclusion criteria to
include the above-mentioned study types to help us determine
the potential of ’Summary of findings’ tables to communicate key
findings of systematic reviews.
Types of data
We will include data from published, unpublished and grey liter-
ature comparing standard/static or interactive ’Summary of find-
ings’ (i’Summary of findings’) tables or both, as described by
GRADE (Guyatt 2011; Guyatt 2013a; Guyatt 2013b; Agoritsas
2015) with other types of summaries of systematic reviews.
We will include studies that recruit any participant type that
uses ’Summary of findings’ tables of systematic reviews including:
patients, families/carers, healthcare professionals, policy makers,
health systemsmanagers, systematic review authors or other stake-
holders.
Types of methods
We will include studies that compare:
• the effects of ’Summary of findings’ tables versus full
versions of systematic reviews on communicating key findings of
systematic reviews of the effects of healthcare interventions;
• the effects of ’Summary of findings’ tables plus full review
versus full review (no ’Summary of findings’ tables);
• the effects of ’Summary of findings’ tables versus other
summaries of systematic reviews on communicating key findings
of systematic reviews of the effects of healthcare interventions;
• the effects of interactive ’Summary of findings’ tables versus
static ’Summary of findings’ tables on communicating key
findings of systematic reviews of the effects of healthcare
interventions.
Types of outcome measures
Primary outcomes
• User understanding of key findings of systematic reviews
measured by the ability to correctly answer factual questions
about the review
• Self-perceived understanding of key findings of systematic
reviews as reported by the user
• Self-reported influence on decision-making
Secondary outcomes
• Time taken to read summary and extract relevant
information
• Accessibility of the main findings of the review
• User satisfaction/preferences/attitudes
• Other outcomes not reported in the protocol whose
importance is realised after the protocol is written or when the
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analysis is done. To address any concerns of bias, a justification
of the outcome inclusion will be provided (Kirkham 2010).
Search methods for identification of studies
At least one article has reported that the first evaluation of ’Sum-
mary of findings’ tables occurred in 2005 (Langendam 2013).
Nevertheless, we do not know for certain that ’Summary of find-
ings’ tables were not mentioned in the literature prior to 2005.
Therefore, we will not apply date restrictions on this search. We
will not use language restrictions. A search strategy for PubMed is
detailed in Appendix 1.
Electronic searches
We will run electronic or manual searches of the following online
resources:
• Electronic databases: the Cochrane Library, the Campbell
Collaboration, PubMed, CINAHL, LILACS, Web of Science,
SCOPUS, Embase, PsycINFO, Epistemonikos.
• International trials registers such as the Cochrane Central
Register of Controlled Trials (CENTRAL), PROSPERO,
ClinicalTrials.gov, WHO International Clinical Trials Registry
Platform (ICTRP) portal.
• Grey literature sources such as reports/dissertations/theses
databases and databases of conference abstracts e.g. Cochrane
Colloquium abstracts, ETHOS, OpenGrey, ISI Web of
Knowledge and websites of key organisations e.g. GRADE,
Epistemonikos.
Searching other resources
Reference lists
We will search reference lists of included studies and similar sys-
tematic reviews to find additional relevant resources.
Correspondence
If deemed appropriate, we will contact individuals or groups
known to have experience or knowledge of ’Summary of findings’
tables e.g. researchers, review authors, members of theDeveloping
and Evaluating Communication Strategies to Support Informed
Decisions and Practice Based on Evidence (DECIDE) collabora-
tion, GRADE Working Group, and the Cochrane Applicability
and Recommendations Methods Group to identify and locate ad-
ditional resources or studies which have not yet been published or
are not readily accessible.
Data collection and analysis
The following methods are based on recommendations described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011) and theMethodological Expectations for theCon-
duct of Cochrane Intervention Reviews (Higgins 2016). Ran-
domised trials will be analysed separately from the other types of
study design.
Selection of studies
Two review authors (Aislinn Conway (AC)) and (Declan Devane
(DD)) will independently screen titles and abstracts of all citations
identified by searches against inclusion criteria based on types of
studies, types of interventions and participants. The citations will
be sorted into the following groups; ’include’, ’full-text review’ and
’exclude’. Both authors will review full versions of papers where it
is unclear whether prespecified eligibility criteria have beenmet. If,
after discussion, there is still disagreement regarding study selec-
tion, a third review author (Mike Clarke (MC)) will be provided
with a full-text copy of the article for comment and judgement
as to whether to include. Reference management software will be
used to import all references from databases and other print and
electronic sources into a single place accessible to authors.
Data extraction and management
Two review authors (AC and DD) will independently complete
tailored data extraction forms for each of the studies. We will dis-
cuss discrepancies and if resolution is not reached, we will consult
a third author.
Items extracted will include the following.
• Authors
• Year of Publication
• Language
• Setting
• Country
• Study design
• Participants:
◦ Professional or non-professional group e.g. patients
◦ Level of experience using ’Summary of findings’ tables
• Intervention:
◦ Characteristics of intervention e.g. format, timing,
setting
• Comparison:
◦ Details of comparison intervention
• Outcomes:
• ◦ User understanding of key findings of systematic
reviews measured by the ability to correctly answer factual
questions about the review
◦ Self-perceived understanding of key findings of
systematic reviews as reported by the user
◦ Self-reported influence on decision-making
◦ Time taken to read summary and extract relevant
information
◦ Accessibility of the main findings of the review
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◦ User satisfaction/preferences/attitudes
◦ Length of time during which outcomes were measured
after initiation of the intervention
◦ Whether follow-up occurred, if so, length of follow-up
and follow-up points
• Data to assess the risk of bias of included studies e.g.
sequence generation, allocation concealment, blinding of study
participants and personnel, blinding of outcome assessors,
withdrawals or incomplete outcome data, selective reporting or
other sources of bias
• Funding sources
Assessment of risk of bias in included studies
Two review authors (AC and DD) will assess the risk of bias for
each study independently. We will use the criteria described in the
Cochrane ‘Risk of bias’ criteria (Higgins 2011) and in section 6.4
of the Data Collection Checklist (EPOC 2010) for randomised
trials and the Cochrane EPOC Review Group guidance on risk
of bias criteria (EPOC 2015) and the Cochrane EPOC Review
Group guidance (EPOC 2013b) if our review includes more than
one study design. Our inclusion of non-randomised studies brings
a greater potential for bias (Higgins 2011). We will contact study
authors when information is missing or if clarification is required.
Two review authors will apply the ’Risk of bias’ criteria to each
study independently and differences will be resolved by consulting
a third review author (ST).
The following criteria are recommended for randomised trials
(RTs), non-randomised trials (NRTs) and cross-over studies.
Selection bias: Random sequence generation
The rules for allocating interventions to participants in the studies
will be reported so that we can identify whether there is a risk that
’Summary of findings’ tables groups and comparison groups may
not have been comparable. We will base our judgements on the
following criteria.
• For randomised trials:
◦ if sequence generation is truly random (e.g. computer
generated random assignment): low risk;
◦ if sequence generation is not specified and we are
unable to obtain relevant information from study authors:
unclear risk;
◦ if there is a quasi-random sequence generation e.g.
alternation: high risk.
• For non-randomised trials: high risk.
Selection bias: Allocation sequence concealment
Prior to the assignment of interventions to participants, steps
should be taken to ensure that knowledge of the allocation se-
quence is not possible. Studies will be deemed at low risk if they
used:
• opaque, sequentially numbered envelopes which were
opened sequentially and not re-assigned;
• central randomisation by a third party.
If the allocation concealment is not specified and we are unable to
ascertain whether the allocation concealment was protected before
and until assignment, the study will be considered as an unclear
risk.
Non-randomised trials and studies which have inadequacies in
their allocation concealment, e.g. if non-opaque envelopes were
used, will be considered at high risk.
Performance Bias: Blinding of participants and
personnel
It will not be possible to blind participants or personnel to the in-
tervention to which they have been assigned because of formatting
differences between systematic reviews, ’Summary of findings’ ta-
bles and other summaries. Therefore, risk of bias for performance
bias will be judged as high risk. Under certain circumstances, it
may be possible to blind for comparisons of different formats of
’Summary of findings’ tables. For example if two static ’Summary
of findings’ tables are being compared. However, without a de-
tailed description of this to allow assessment, risk of bias will be
judged as high risk.
Detection Bias: Blinding of outcome assessors
Wewill judge the risk of detectionbias for studies based onwhether
the assessors have knowledge of the intervention received by par-
ticipants, using the following criteria:
• if subjective outcomes were not assessed blindly e.g. self-
perceived understanding of key findings of systematic reviews (as
reported by the user): high risk;
• if outcomes were assessed blindly: low risk;
• if objectives outcomes were not assessed blindly e.g. open-
ended questions in user understanding of key findings test: low
risk;
• if we cannot ascertain whether assessors were blinded and
study authors do not provide information to clarify: unclear risk.
Attrition Bias: Incomplete outcome data
We will explore whether withdrawals or incomplete outcome data
due to exclusions or attrition may have occurred in randomised
and non-randomised studies (including cross-over trials). We will
also investigate the spread of missing data across groups. The risk
of this bias will be judged using the following criteria:
• if 20% or more of the data are missing or if the missing data
are not equally spread across groups: high risk;
• if less than 20% of the data are missing and are spread
equally across groups: low risk;
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• if the percentage of missing data or the spread of missing
data are not clear: unclear risk.
Selective reporting bias
Wewill investigate whether all outcomes mentioned in methodol-
ogy sections of randomised and non-randomised studies (includ-
ing cross-over trials) are reported in results sections. We will assess
this using the following criteria:
• if all outcomes in the methodology are not reported in the
results or if outcomes reported in the results were not listed in
the methodology: high risk;
• if outcomes specified in randomised trial protocols a priori
are not reported in the results or if outcomes reported in the
results are not listed in the protocol: high risk;
• if outcomes are only partly reported in the results or if an
obvious outcome is not mentioned in the study: high risk;
• if all outcomes are both listed in the methodology and
reported in the results: low risk.
Other potential sources of bias
We will assess the randomised and non-randomised studies for
other potential biases (e.g. recruitment bias: imbalance in patient
characteristics) using the following criteria:
• If there is one or more important risks of bias e.g. flawed
study design: high risk;
• If there is no evidence of other sources of bias: low risk;
• If there is incomplete information regarding a problem
which may lead to bias: unclear risk.
We will further assess cross-over trials using the following criteria
outlined in Section 16.4.3 of theCochrane Handbook for Systematic
Reviews of Interventions:
• suitability of the cross-over design;
• whether there is a carry-over effect;
• whether only first period data are available;
• whether the analysis is correct;
• comparability of results with those from parallel-group
trials.
Measures of the effect of the methods
Dichotomous data (correct/incorrect answers on tests of under-
standing of key findings of systematic reviews) will be determined
using a risk ratio (RR) with a 95% confidence interval (CI).
Ordinal scale data outcomes reported in this waywill be collapsed
into dichotomous outcomes.
Continuous data will be analysed using mean difference (MD)
with the 95% CI if the measurement scale is the same. If the scale
is different, standardised mean differences (SMD) with 95% CIs
will be used.
Unit of analysis issues
Randomised trialswill be analysed separately from the other types
of study design.
Cluster-randomised trials included in the systematic review will
be identified as such. We will report the baseline comparability of
clusters and consider statistical adjustment if it may help to reduce
an imbalance.
We will estimate the intracluster correlation coefficient (ICC) as
described by Higgins 2011 using information from the study if it
is available or, from an external estimate obtained from a similar
study. If we do this, we will conduct sensitivity analyses to explain
variation in ICC values.
Studies with multiple intervention groups we will include and
analyse groups which are relevant to our review. However, all in-
tervention groups will be clearly listed in the ‘Characteristics of
included studies’ table. To avoid “double counting” data for stud-
ies that could contribute more than one control group, we will
combine comparison groups to create a single pair-wise compari-
son (Higgins 2011).
Dealing with missing data
We will contact authors when a gap is identified in studies. If we
decide that there may be reasons to impute missing data e.g. to
explore the impact of missing data in the sensitivity analysis, we
will discuss the potentials harms and benefits of this. If themissing
data are substantial, analysis with imputed data may be futile.
We will narratively explore the potential impact of missing data
in the discussion section of the review.
Assessment of heterogeneity
We have specified that we will include non-randomised trials in
this review which may lead to increased statistical heterogeneity.
We will assess heterogeneity by visually inspecting a forest plot of
included studies. The location of point estimates, the degree to
which confidence intervals overlap and the presence and results of
meta-analysis will be taken into account. Next, we will test for the
presence of heterogeneity using the Chi2 test. If the P value is low
(less than 0.10), the likelihood of heterogeneity will increase.
We will quantify the extent of heterogeneity by calculating an
estimation of the I2 statistic. We will follow the guidance outlined
in Section 9.5.2 of the Higgins 2011:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity*;
• 50% to 90%: may represent substantial heterogeneity*;
• 75% to 100%: considerable heterogeneity*.
*The importance of the observed value of I2 depends on (i) mag-
nitude and direction of effects and (ii) strength of evidence for
heterogeneity (e.g. P value from the Chi2 test, or a confidence
interval for I2). If our I2 value indicates that heterogeneity is a
possibility and either the Tau2 is greater than zero, or the P value
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is low (less than 0.10), heterogeneity may be due to a factor other
than chance.
If we identify methodological or statistical heterogeneity, we will
not pool results into a meta-analysis. Instead we will carry out a
narrative synthesis, grouping trials with similar populations and
interventions together to attempt to identify reasons for hetero-
geneity.
Assessment of reporting biases
If 10 or more studies are included in a meta-analysis, we will create
a funnel plot to investigate whether bias may exist unless all stud-
ies are of a similar size. We will use the funnel plot test proposed
by Egger 1997. If we notice asymmetry we cannot conclude that
reporting biases exist however, we will consider the sample sizes
and presence and possible influence of outliers. We will discuss
potential explanations such as publication bias or poor method-
ological quality of included studies and subsequently perform a
sensitivity analysis.
Data synthesis
We will use Review Manager software (RevMan 2014) to conduct
our statistical analysis and undertake meta-analysis if it is deemed
appropriate. Considering the differences in the participant groups,
the comparisons and the outcomes in this review, we will use a
random-effects model. The pooled estimate of the effects will es-
timate the mean effects across the groups, comparisons and meth-
ods of outcome evaluation. Both within-study and between study
variability will be addressed.
If we do not deem it appropriate to conduct meta-analyses we will
present a systematic, narrative summary of the results.
’Summary of findings’ table
Two review authors (AC, DD) will assess the quality of the evi-
dence. Based on the methods described in Section 8.5 of chap-
ter 12 of the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011) and by GRADE (Guyatt 2013a; Guyatt
2013b), we will create ’Summary of findings’ tables for the main
comparisons of the review: ’Summary of findings’ tables versus full
versions of systematic reviews; ’Summary of findings’ tables plus
full review versus full review (no ’Summary of findings’ tables);
’Summary of findings’ tables versus other summaries of systematic
reviews; and interactive versus static ’Summary of findings’ tables.
We will present the following primary and secondary outcomes for
each comparison: user understanding of key findings of systematic
reviews, self-perceived understanding of key findings of system-
atic and self-reported influence on decision-making, time taken
to read summary and extract relevant information, accessibility
of the main findings of the review, user satisfaction/preferences/
attitudes and other outcome(s) of main interest, as outlined in the
section on Types of outcome measures. We will describe the study
settings and number of participants and studies addressing each
outcome. For each assumed risk cited in the table(s), we will pro-
vide a source and rationale, and the GRADE system will be used
to assess the quality of the evidence using GRADEpro software or
the GRADEpro GDT app. If meta-analysis is not appropriate or
the units of analysis cannot be compared, we will present results in
a narrative ’Summary of findings’ table format (using Chan 2011
for guidance). If we do this, the imprecision of the evidence will be
an issue of concern due to the lack of a quantitative effect measure.
Subgroup analysis and investigation of heterogeneity
If visual inspection of forest plots, Chi2 test, I2 statistic and Tau2
indicate that statistical heterogeneity could be present, a subgroup
analysis will be carried out.
A subgroup analysis will be deemed appropriate if included studies
satisfy criteria to assess credibility of subgroup analyses (Oxman
1992; Sun 2010).
The following are our a priori subgroups:
• different participant groups e.g. patients, policy makers or
healthcare professionals;
• intervention characteristics e.g. different formats of
’Summary of findings’ tables, different summarisation products;
• type of study.
Sensitivity analysis
Wewill use theGRADEapproach (Guyatt 2008) to assess the level
of quality of the evidence and thereby, interpret the results. This
involves the GRADE classification terms: high, moderate, low or
very low. GRADE is characterised by eight criteria for authors to
consider (Schünemann 2013).
• Risk of bias (potential to reduce level of quality of evidence
by one or two levels)
• Inconsistency of results (potential to reduce level of quality
of evidence by one or two levels)
• Indirectness of evidence (potential to reduce level of quality
of evidence by one or two levels)
• Imprecision of results (potential to reduce level of quality of
evidence by one or two levels)
• Risk of publication bias (potential to reduce level of quality
of evidence by one or two levels)
• Magnitude of effect (potential to increase level of quality of
evidence by one or two levels)
• Dose response gradient (potential to increase level of quality
of evidence by one level)
• Influence of residual plausible confounding (potential to
increase level of quality of evidence by one level)
We will downgrade randomised trials by one, two or three levels
according to the severity of the study limitations (the first five
factors listed above). We will upgrade non-randomised trials if
their results show large effects and bias is not evident, or we will
downgrade them if they demonstrate limitations as listed above.
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We will use The GRADEpro Guideline Development Tool to
create a ’Summary of findings’ table incorporating our results.
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Appendix 1. PubMed search strategy
Platform: part of the Entrez series of databases provided by the NLM National Center for Biotechnology Information (NCBI)
Years of coverage: generally 1946 to the present, with some older material
Date conducted: 13/01/2016
#1 “summary of findings” OR summary-of-findings
#2 table OR tables OR tabulate* OR tabular
#3 #1 AND #2
Limits: none
No. of hits: 100
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